We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Sigma-Proligo Expands into Genopole® d'Evry Biopark


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sigma-Proligo Expands into Genopole® d'Evry Biopark"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Sigma-Proligo, a division of the Sigma-Aldrich group has announced it has acquired 2,000 sq. meters of office space in the heart of the Genopole® d'Evry biopark in the region of Paris. The official inauguration has took place on October 19 at 11:30 a.m.

Sigma-Proligo provides researchers throughout the world with high-quality oligonucleotides due to a high throughput synthesis platform.

With 65 employees in France, the majority of whom are researchers, Sigma-Proligo has expertise in nucleic acid synthesis and holds several key patents in siRNA gene silencing technology.

The new facility is expected to provide the capacity needed for the Company to advance the production of high-quality oligonucleotides in order to meet emerging needs within the bioscience research sector.

Sigma-Proligo develops protocols and methods in the field of oligonucleotides, and is one of four companies with the MIT license on siRNAs.

"The 'biotech' image of Genopole, as well as the offices and working environment perfectly adapted to our operations, have been the main reasons behind our expansion into Evry," said Khalil Arar, operations manager of Sigma-Aldrich Evry.

"The RNAi market has a predicted compound annual growth rate of 14%, and these new facilities are expected to provide Sigma-Proligo with the capacity to meet the increasing market demand for RNAi products."

"The facilities should also enable the Company to continue to supply customers with innovative products."

Thierry Mandon, President of Genopole, said, "A mature company moving onto the campus boosts the attractiveness of Evry-Corbeil as a business location, and demonstrates its credibility in the biotech sector."

Pierre Tambourin, CEO of Genopole, added, "This move will promote interactivity with our start-ups, which will profit from Sigma Proligo's knowledge, and our larger companies who need dynamic local links in order to pursue their development."

Marc Rebois, Director of SEM Genopole, the company that creates and manages the site's real estate and business accommodation resources, added, "Welcoming such a well-known company to Evry-Corbeil is a reward for our ongoing focus on truly biotech-dedicated real estate solutions, and it also constitutes recognition of our campus on the international level."

Advertisement